Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Alpha Radiation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43895   clinical trials with a EudraCT protocol, of which   7301   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    43 result(s) found for: Alpha Radiation. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2005-004078-25 Sponsor Protocol Number: VEG105192 Start Date*: 2006-03-16
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients with Locally Advanced and/or...
    Medical condition: Locally Advanced and/or metastatic renal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10050076 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) SK (Completed) LT (Completed) EE (Completed) AT (Completed) CZ (Completed) IT (Completed) GR (Prematurely Ended) HU (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2016-000758-37 Sponsor Protocol Number: NO18517 Start Date*: 2016-08-23
    Sponsor Name:F. Hoffmann-La Roche AG
    Full Title: A Phase I Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas and High Grade Gliomas
    Medical condition: High Grade Glioma Brainstem Glioma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006143 Brain stem glioma PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-001152-39 Sponsor Protocol Number: SSG XX Start Date*: 2024-05-21
    Sponsor Name:Scandinavian Sarcoma Group
    Full Title: SSGXX A Scandinavian Sarcoma Group treatment protocol for adult patients with non-metastatic high-risk soft tissue sarcoma of the extremities and trunk wall
    Medical condition: SSG XX is a phase II trial for high-risk soft tissue sarcoma(STS) of the extremities and trunk wall. Prognostic markers are used to identify high-risk tumors. SSG XX will evaluate chemo-and radioth...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing) SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003655-66 Sponsor Protocol Number: I4T-MC-JVDC Start Date*: 2015-04-30
    Sponsor Name:Lilly S.A
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab plus Docetaxel versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial ...
    Medical condition: Locally advanced or unresectable or metastatic urothelial carcinoma who have had disease progression on or after one prior first-line platinum-based chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed) DK (Completed) DE (Completed) NL (Completed) PL (Completed) GB (GB - no longer in EU/EEA) BE (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000121-19 Sponsor Protocol Number: CapRI 2 Start Date*: 2008-08-11
    Sponsor Name:University of Heidelberg
    Full Title: A Randomized Multicentre Phase II Trial Comparing Adjuvant Therapy in Patients with Resected Pancreatic Adenocarcinoma Treated with Interferon Alpha-2b and 5-FU Alone or in Combination with Either ...
    Medical condition: Patients with Resected Pancreatic Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033608 Pancreatic cancer resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005770-72 Sponsor Protocol Number: 0681 Start Date*: 2006-01-13
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA
    Full Title: RAPSODY - RANDOMIZED, PROSPECTIVE TRIAL OF TWO SCHEDULES OF SORAFENIB 800 mg DAILY AND INTERFERON ALPHA IN METASTATIC RENAL CELL CARCINOMA MRCC A GOIRC PHASE II STUDY
    Medical condition: Patients with histologically- or cytologically-confirmed, metastatic, clear cell renal cell cancer RCC
    Disease: Version SOC Term Classification Code Term Level
    6.1 10050513 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2007-004699-38 Sponsor Protocol Number: RCCC10 Start Date*: Information not available in EudraCT
    Sponsor Name:Klinikum der Universität Regensburg
    Full Title: A prospective phase I/II, one-arm, multi-center, open label study of pioglitazone in combination with sorafenib and low dose IFN alpha in metastatic, non-resectable renal clear cell carcinoma
    Medical condition: To investigate the effect of an anti-inflammatory therapy consisting of pioglitazone (Actos) in combination with an angiostatic treatment with sorafenib (Nexavar) and Interferin-Alpha (Roferon) on ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038416 Renal clear cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004089-33 Sponsor Protocol Number: CHDR1317 Start Date*: 2013-11-26
    Sponsor Name:Centre for Human Drug Research
    Full Title: A Phase 1, Open Label, Exploratory Study for the Intra-operative Imaging of Folate Receptor Alpha Positive Ovarian and Lung Cancer using the Tumor Specific Imaging Agent EC17
    Medical condition: primary ovarian carcinoma and primary non small cell lung carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006446-33 Sponsor Protocol Number: CSTI571 basket 1 Start Date*: 2007-03-20
    Sponsor Name:ITALIAN SARCOMA GROUP
    Full Title: Open-label trial of Imatinib in patients with Desmoid Tumor and Chondrosarcoma
    Medical condition: Patients with Desmoid Tumor and Chondrosarcoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039491 Sarcoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003847-22 Sponsor Protocol Number: ICORG11-04 Start Date*: 2012-02-02
    Sponsor Name:ICORG
    Full Title: ECOG 2809: Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
    Medical condition: Patients with Rising PSA at high risk of Prostate cancer progression
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071119 Hormone-dependent prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002961-23 Sponsor Protocol Number: ODO-TE-B301 Start Date*: Information not available in EudraCT
    Sponsor Name:Odonate Therapeutics, Inc.
    Full Title: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally...
    Medical condition: Patients with Breast Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) HU (Completed) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) DE (Completed) BE (Prematurely Ended) FR (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-003592-34 Sponsor Protocol Number: IMGN853-0419 Start Date*: 2021-12-21
    Sponsor Name:ImmunoGen, Inc.
    Full Title: PICCOLO: A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Rece...
    Medical condition: Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061269 Malignant peritoneal neoplasm PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing) BE (Completed) IT (Ongoing) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000928-71 Sponsor Protocol Number: GOIRC02/2008-TWIST Start Date*: 2008-11-14
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA
    Full Title: “TWIST”. RANDOMIZED PROSPECTIVE PHASE II STUDY OF TEMSIROLIMUS WITH OR WITHOUT LOW-DOSE INTERFERON ALPHA IN METASTATIC NON-CLEAR RENAL CELL CARCINOMA: GOIRC STUDY 02/2008
    Medical condition: Patients with advanced non-clear Cell Renal Carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    9.1 10038458 Renal granular cell carcinoma PT
    9.1 10038414 Renal cell carcinoma stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004501-24 Sponsor Protocol Number: CT-2011-01 Start Date*: 2012-03-06
    Sponsor Name:CureTech Ltd.
    Full Title: Phase II study to evaluate the safety, tolerability and efficacy of CT-011 administered intravenously to patients with metastatic melanoma
    Medical condition: Metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016489-10 Sponsor Protocol Number: TPF-C-HIT Start Date*: 2010-08-23
    Sponsor Name:University of Heidelberg
    Full Title: Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanc...
    Medical condition: The study is a phase II study of induction chemotherapy with docetaxel plus cisplatin and fluorouracil (TPF) followed by radioimmunotherapy with Cetuximab and intensity modulated radiotherapy (IMRT...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003509-80 Sponsor Protocol Number: IMGN853-0416 Start Date*: 2020-09-07
    Sponsor Name:ImmunoGen, Inc.
    Full Title: MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Periton...
    Medical condition: Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061269 Malignant peritoneal neoplasm PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Ongoing) BG (Ongoing) GB (GB - no longer in EU/EEA) FR (Ongoing) DE (Ongoing) PL (Ongoing) PT (Ongoing) NL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004359-57 Sponsor Protocol Number: CanStem111P Start Date*: 2017-08-01
    Sponsor Name:Sumitomo Dainippon Pharma Oncology, Inc.
    Full Title: A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma.
    Medical condition: This study will enroll patients with histologically or cytologically confirmed adenocarcinoma of the pancreas that is metastatic (Stage IV).
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) NL (Completed) BE (Completed) CZ (Completed) AT (Completed) PT (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000912-34 Sponsor Protocol Number: PR003-CLN-pro001 Start Date*: 2008-05-07
    Sponsor Name:Protherics Development Medicines Ltd
    Full Title: A PHASE 2 STUDY OF THE ANTI-TUMOUR ACTIVITY AND SAFETY OF PROLARIX™ IN HEPATOCELLULAR CARCINOMA (HCC)
    Medical condition: Hepatocellular Carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019318-26 Sponsor Protocol Number: IMCL_CP12-0919_(I4T-IE-JVBF) Start Date*: 2010-09-27
    Sponsor Name:ImClone LLC
    Full Title: A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepato...
    Medical condition: Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) CZ (Completed) PT (Completed) BE (Completed) ES (Completed) AT (Completed) FR (Completed) BG (Completed) HU (Completed) IT (Completed) SE (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2005-002738-36 Sponsor Protocol Number: G-0029 Start Date*: 2005-11-08
    Sponsor Name:Cell Genesys Inc
    Full Title: A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients with Metastatic Hormone-Refractory Prostate Cancer who are Chemotherapy-Naïve
    Medical condition: Metastatic Hormone-Refractory Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    8.0 10036909
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended) SE (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 30 17:50:53 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA